Discovery of a 2,4-diphenyl-5,6-dihydrobenzo(h)quinolin-8-amine derivative as a novel DNA intercalating topoisomerase IIα poison.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Dec 2021
Historique:
received: 13 07 2021
revised: 04 09 2021
accepted: 17 09 2021
pubmed: 2 10 2021
medline: 27 1 2022
entrez: 1 10 2021
Statut: ppublish

Résumé

Several anticancer agents have been developed and innovative approaches have been made toward cancer type-specific medicines for cancer treatment. As a continuous effort to develop potential chemotherapeutic agents, a novel series of 2,4-diphenyl-5,6-dihydrobenzo(h)quinolin-8-amines containing amino groups, hydroxyphenyl and fluorine functionalities were designed and synthesized. The compounds were evaluated for topo IIα inhibitory and cytotoxicity against HCT15, and HeLa human cancer cell lines. Among synthesized thirty compounds, the majority exhibited strong topo IIα inhibition and anti-proliferation against HCT15 colorectal adenocarcinoma cell line. The structure-activity relationship study revealed that compounds with -CF

Identifiants

pubmed: 34597897
pii: S0223-5234(21)00709-1
doi: 10.1016/j.ejmech.2021.113860
pii:
doi:

Substances chimiques

Amines 0
Antineoplastic Agents 0
Topoisomerase II Inhibitors 0
DNA Topoisomerases, Type II EC 5.99.1.3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113860

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Surendra Kunwar (S)

College of Pharmacy, Yeungnam University, Gyeongsan, 38541, Republic of Korea.

Soo-Yeon Hwang (SY)

College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Global Top 5 Program, Ewha Womans University, Seoul, 120-750, Republic of Korea.

Pramila Katila (P)

College of Pharmacy, Yeungnam University, Gyeongsan, 38541, Republic of Korea.

Seojeong Park (S)

College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Global Top 5 Program, Ewha Womans University, Seoul, 120-750, Republic of Korea.

Kyung-Hwa Jeon (KH)

College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Global Top 5 Program, Ewha Womans University, Seoul, 120-750, Republic of Korea.

Daeun Kim (D)

College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Global Top 5 Program, Ewha Womans University, Seoul, 120-750, Republic of Korea.

Tara Man Kadayat (TM)

College of Pharmacy, Yeungnam University, Gyeongsan, 38541, Republic of Korea.

Youngjoo Kwon (Y)

College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Global Top 5 Program, Ewha Womans University, Seoul, 120-750, Republic of Korea. Electronic address: ykwon@ewha.ac.kr.

Eung-Seok Lee (ES)

College of Pharmacy, Yeungnam University, Gyeongsan, 38541, Republic of Korea. Electronic address: eslee@yu.ac.kr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH